Vaxcyte, Inc. Quarterly Debt-to-equity in % from Q1 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Vaxcyte, Inc. quarterly Debt-to-equity history and growth rate from Q1 2021 to Q3 2024.
  • Vaxcyte, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 6 %, a 2.04% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 6 +0.12 +2.04% Sep 30, 2024
Q2 2024 7.1 +0.64 +9.92% Jun 30, 2024
Q1 2024 7.22 -0.93 -11.4% Mar 31, 2024
Q4 2023 7.84 -1.66 -17.5% Dec 31, 2023
Q3 2023 5.89 -7.36 -55.6% Sep 30, 2023
Q2 2023 6.45 -6.98 -52% Jun 30, 2023
Q1 2023 8.15 -5.48 -40.2% Mar 31, 2023
Q4 2022 9.5 -5.49 -36.6% Dec 31, 2022
Q3 2022 13.2 -1.54 -10.4% Sep 30, 2022
Q2 2022 13.4 -0.1 -0.74% Jun 30, 2022
Q1 2022 13.6 +1.29 +10.5% Mar 31, 2022
Q4 2021 15 Dec 31, 2021
Q3 2021 14.8 Sep 30, 2021
Q2 2021 13.5 Jun 30, 2021
Q1 2021 12.3 Mar 31, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.